Boston Scientific beats Q3 estimates; raises FY 2023 adjusted EPS guidance to $1.99-2.02

BOSTON SCIENTIFIC CORP

2023-Q3 EPS reported $0.73 revenue$10,515,000,000

Q3 net sales $3.527B (+11.2% reported, +10.2% organic); beat guidance of 8.5-10.5% reported and 7-9% organic.
GAAP EPS $0.34 (vs guidance $0.21-0.25); adjusted EPS $0.50 (vs guidance $0.46-0.48), up from $0.43 a year ago.
Cardiovascular sales $2.185B (+11.6% reported); MedSurg $1.341B (+10.6%); U.S. grew 8.5%, Asia-Pacific 14.8% reported.
FY 2023 guidance raised: organic sales growth ~11%; GAAP EPS $1.00-1.04; adjusted EPS $1.99-2.02 (prev. $1.94-1.98).
Announced agreement to acquire Relievant Medsystems (Intracept system) for vertebrogenic pain; terms not disclosed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BOSTON SCIENTIFIC CORP reported third quarter ended September 30, 2023 results: revenue $3.527 billion, net income $505 million or $0.34 per share, EPS $0.50.

Period: third quarter ended September 30, 2023
Revenue: $3.527 billion
Net income: $505 million or $0.34 per share
EPS: $0.50
Result: reported results

Exact text from the filing

Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.527 billion during the third quarter of 2023, growing 11.2 percent on a reported basis, 11.1 percent on an operational 1 basis and 10.2 percent on an organic 2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $505 million or $0.34 per share (EPS), compared to $174 million or $0.12 per share a year ago, and achieved adjusted 3 EPS of $0.50 for the period, compared to $0.43 a year ago.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

BOSTON SCIENTIFIC CORP filing history →

Source: SEC EDGAR

accession 0000885725-23-000045

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.